drugset / Trial / NCT00211458

Treatment of Age-Related Macular Degeneration With Anecortave Acetate

NCT00211458

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to provide compassionate use of anecortave acetate sterile suspension of 15 mg for a series of five patients as a means to control classic neovascularization following failure of treatment with photodynamic therapy using Visudyne.

Timeline

Start
2005-09
Primary completion
2007-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Anecortave Acetate Small molecule 15 mg

Indications